drugset
drugset / Trial / NCT00403052

A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer

NCT00403052 ↗

Phase 1 Terminated 14 enrolled Dynavax Technologies Corporation
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The main objectives of this study are to establish a safe, tolerable and active dose of 1018 ISS administered in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer. Other objectives also include determining tumor response, time to disease progression, and overall survival in treated patients.

Timeline

Start
2006-11
Primary completion
2007-12
Completion
2007-12

Outcome

Outcome not reported

Stopped: “Administrative reasons”

Drugs

EvaluationDrugModalityDoseRoute
Subject 1018 ISS immunostimulatory oligonucleotide Oligonucleotide (other) — Subcutaneous

Indications

colorectal neoplasm